Advertisement
Advertisement
CLDX
Celldex Therapeutics, Inc
33.51
USDSponsored
-4.38
-11.56%
Sep 22, 15:59 UTC -4
Closed
Pre-Market
33.70
+0.20
+0.58%
CLDX Earnings Reports
Positive Surprise Ratio
CLDX beat 29 of 42 last estimates.
69%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$721.28K
/-$1.04
Implied change from Q2 26 (Revenue/ EPS)
+3178.55%
/+10.64%
Implied change from Q3 25 (Revenue/ EPS)
--
/+2.97%
Celldex Therapeutics, Inc earnings per share and revenue
On Aug 06, 2026, CLDX reported earnings of -0.94 USD per share (EPS) for Q2 26, beating the estimate of -1.07 USD, resulting in a 12.79% surprise. Revenue reached 22.00 thousand, compared to an expected 973.53 thousand, with a -97.74% difference. The market reacted with a +0.36% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -1.04 USD, with revenue projected to reach 721.28 thousand USD, implying an increase of 10.64% EPS, and increase of 3178.55% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Celldex Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Celldex Therapeutics, Inc reported EPS of -$0.94, beating estimates by 12.79%, and revenue of $22.00K, -97.74% below expectations.
How did the market react to Celldex Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 0.36%, changed from $41.56 before the earnings release to $41.71 the day after.
When is Celldex Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Celldex Therapeutics, Inc's next earnings report?
Based on 10
analysts, Celldex Therapeutics, Inc is expected to report EPS of -$1.04 and revenue of $721.28K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.